tiology of the disease) are associated with increased TGF ␤ and CTGF expression levels which, in turn, have an inverse effect on the activity level of BMP-7 and HGF, leading to an EMT of injured tubular epithelial cells and a progression of the disease. A detailed understanding of the complex interrelationship between these growth factors may lead to the development of novel drugs.
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is widely accepted, their precise origin and fate is still debated [4, 5] . It has been suggested that they may be derived from a heterogeneous origin such as resident fibroblasts, bone marrow, circulating fibrocytes, perivascular smooth muscle cells or local EMT. EMT is also thought to cause the tubular atrophy associated with TIF [6] . The process of EMT was first demonstrated by Strutz et al. [7] and confirmed by the study of Iwano et al. [6] using genetic tagging of renal tubules in mice. However, the in vivo evidence of EMT as the major mediator of the pathogenesis and progression of TIF in chronic kidney diseases is not yet conclusive [8] [9] [10] .
Events Occurring during EMT
EMT is a program whereby epithelial cells that function as ion and fluid transporters become matrix remodelling cells. Thus cells: (1) Lose their epithelial polarity, cellular adhesion molecules, cell-cell and cell-matrix contacts. (2) Reorganize their actin cytoskeleton from a cortical bundle formation that supported adhesion molecules into stress fibres containing de novo expressed ␣ -smooth muscle actin ( ␣ -SMA) that support migration and matrix remodelling; cells also exchange their cytokeratin intermediate filaments for a vimentin profile. (3) Express S100A4 that interacts with actin and myosin heavy chain IIA to enhance cell motility. (4) Disrupt the tubular basement membrane (TBM) and migrate into the interstitium where they synthesise increasing amounts of extracellular matrix (ECM) [11] .
Regulators of EMT
Numerous in vitro studies have shown that EMT is regulated by growth factors, cytokines, metalloproteinases (MMPs) which can disrupt the TBM integrity [12, 13] and alteration in the TBM composition [12] . Currently, transforming growth factor (TGF) ␤ 1 is the main growth factor reported to mediate the initiation and maintenance of the EMT process. The role and the possible molecular mechanisms whereby TGF ␤ functions were recently reviewed extensively by Zavadil and Bottinger [5] . Thus the present article will focus on the interrelationship between TGF ␤ and other growth factors reported to be involved in EMT ( fig. 1 ) .
The EMT process requires either transcriptional repression of genes that maintain the epithelial phenotype (e.g. E-cadherin, claudins, occludins, desmoplakin, desmoglein, ␣ 6 ␤ 4 integrins) and transcriptional activation, or relieved repression of genes needed for functional myofibroblasts (e.g. FN-EDA + , vimentin, ␣ -SMA). This occurs via induction of several transcription repressors that recognize specific motifs in the target promoters (e.g. snail/Slug, SIP1, Twist), via co-repressors that interact with and inactivate transcriptional factors (e.g. TGIF and SnoN) or via regulation of the level of inhibitors of differentiation (Id proteins) which can act as positive regulators of cell proliferation and negative regulators of cell differentiation [14] . These transcriptional regulators are under the control of several integrated signalling pathways including Smads, ERK MAPK, JNK, p38 MAPK, PI3K, NF B and the Rho/ROCK pathways which can be triggered by TGF ␤ [5] and other growth factors.
Growth Factors Which Mediate TGF ␤ Action
Connective tissue growth factor (CTGF) is an immediate-early product and a master mediator of the profibrotic actions of TGF ␤ [15] [16] [17] . It promotes fibroblast proliferation, differentiation and ECM production [18] . In vitro, CTGF is rapidly induced in renal tubular epithelial cells (TECs) by TGF ␤ in a Smad3/Smad4-dependent manner [19] . Elevated expression of CTGF is also reported in TECs and interstitial cells at the sites of chronic interstitial damage [20] . Moreover, CTGF was identified among the genes upregulated in the unilateral ureteral obstruction (UUO) animal model of TIF, using Affymetrix gene microarrays [21] . The crucial role of CTGF in mediating EMT in vitro was demonstrated by its direct ability to induce the process when added exogenously to TECs, and by the blockade of TGF ␤ -induced EMT when CTGF antisense oligodeoxynucleotides (CTGF-AO) were used to deplete endogenous CTGF in TGF ␤ -stimulated cells [22] . Moreover, administration of CTGF-AO attenuated the induction of CTGF, FN, FN-EDA + , ␣ 1 (type I) collagen and ␣ -SMA genes as well as the interstitial fibrotic areas in the UUO model, despite the elevated TGF ␤ gene expression which was not affected [20] . Similarly, Okada et al. [23] have shown that administration of CTGF-AO blocked CTGF expression in the TECs of the remnant kidney of TGF ␤ 1 -transgenic mice, which were subtotally nephrectomized. Again, in these experiments a sustained elevation of TGF ␤ 1 mRNA was observed, despite the significant suppression of TIF in these animals. These findings indicate that CTGF is likely to have a direct effect on inducing EMT in vivo . It has been reported that epidermal growth factor, basic fibroblast growth factor and platelet-derived growth factor-BB can induce EMT in vitro, but to a lesser extent than TGF ␤ . However, they exhibit an enhancer effect when added with TGF ␤ 1 to promote EMT [24] [25] [26] . These growth factors are known to signal via tyrosine kinase receptors that activate the same intracellular signalling pathways which integrate with the Smad pathway. Expression of basic fibroblast growth factor is elevated in injured TECs and is thought to contribute to EMT during renal damage in immune-mediated injury [25, 27] , mainly by increasing the level of MMP-2 and MMP-9 secretion, essential for the disruption of TBM. The inflammatory cytokine tumor necrosis factor-␣ produced by macrophages is also thought to accelerate TGF ␤ -induced EMT [28] via the activation of p38 MAPK and NF B transcription factors. Growth Factors Which Induce TGF ␤ Angiotensin II has been reported to induce the expression of TGF ␤ and CTGF [29] and is thus able to promote EMT in TECs [30] . Other factors such as interleukin (IL)1 and IL-8 induce EMT via a TGF ␤ -dependent pathway [31] but evidence that oncostatin M does so in a similar manner is so far lacking [32] . Other EMT inducers such as advanced glycation end products have been reported to act through both TGF ␤ -dependent and independent pathways [33] .
Growth Factors Which Antagonize TGF ␤ Action
Hepatocyte growth factor (HGF) has been shown to completely block TGF ␤ -induced EMT, to enhance matrix degradation in vitro and to reverse established TIF in animal models of chronic renal injury by inhibiting the TGF ␤ function [34] . The mechanism underlying this ability is thought to involve the induction of the Smad transcriptional co-repressors SnoN and TGIF, which in turn interact with and inactivate the activated Smad complexes, thereby repressing the transcription of several TGF ␤ -responsive genes, including CTGF and ␣ -SMA [35, 36] . HGF administration is reported to restore the level of SnoN and TGIF protein expression which are downregulated in the kidney of animal models of chronic renal injury.
Bone morphogenic protein-7 (BMP-7) is an essential growth factor during kidney development as it regulates branching morphogenesis via MET [37] . In the adult kidney, BMP-7 maintains the function of the renal epithelium. Acute and chronic tubular injury is associated with the downregulation of BMP-7 expression [38] . Recombinant BMP-7 has been shown to reverse TGF ␤ -induced EMT in cultured TECs, and its administration led to the repair of severely damaged renal TECs and to improved renal function in animal models of chronic renal injury and fibrosis [39] . The underlying mechanism is thought to involve the induction of Id proteins by BMP-7 [40] . This is inhibited by TGF ␤ which promotes EMT. Ids lack a basic DNA binding region, but they possess a HLH dimerization motif which allows them to interact with and inactivate bHLH transcription factors that can be inhibitors or activators of transcription. CTGF, plasminogen activator inhibitor-1 (PAI-1) and thrombospondin-1 are among those TGF ␤ responsive genes that are directly downregulated by BMP-7 [41] . The blocking of TGF ␤ -dependent upregulation of PAI-1 by BMP-7 also results in an induced expression of active MMP-2, which promotes the degradation of the fibrotic matrix [38] . This blocking may also enhance the activity of the urokinasetype plasminogen activator, a known activator of HGF [42, 43] .
Smad6 and Smad7 as Regulators of EMT
TGF ␤ and BMP-7 signalling pathways are tightly regulated through both positive and negative mechanisms. One of these negative feedback mechanisms is the production of inhibitory Smads (Smad6/7). Whereas Smad6 preferentially inhibits BMP signalling, Smad7 inhibits the TGF ␤ /activin signalling pathway [44] .
Smad7 binds E3-ubiquitin ligases of the smurf family which cause ubiquitination and proteasomal degradation of the TGF ␤ receptors [45] and prevents the phosphorylation of Smad2 and Smad3, providing a negative feedback loop mechanism to shut off the TGF ␤ signal and limit its effects [46] . Reduction of the Smad7 expression level has been reported in the UUO animal model of TIF [47] , while its forced expression blocks TGF ␤ -induced EMT and ECM synthesis [48] . Smad7 is an immediate-early target gene for both TGF ␤ and BMP-7. While TGF ␤ induces its expression via a Smad binding element site that is regulated by Smad 3/4, AP-1, SP1, and TFE3; BMP-7 induces its expression via multiple BMP responsive elements (BRE). Two low-affinity sites, BRE-1/2, are activated at high concentrations of BMP and 1 high-affinity site, I-BRE, is also activated at low BMP concentrations. BRE-1 binds the Smad1/4 complex whereas I-BRE binds the Smad1/4/GATA complex [44] . This suggests that the presence of GATA transcription factors may enhance Smad7 induction leading to a blockade of TGF ␤ signalling and allowing BMP to signal even at low concentrations.
Smad6 is an immediate-early gene product of BMP signalling. However, its expression requires the cooperative association between the transcription factor CREB and the Smad1/5/4 complex [49] . Smad6 does not only inhibit the activation of R-Smads (Smad1/5/8) and the heteromerization of R-Smad-Smad4, but also acts directly as a transcriptional (co)repressor [50, 51] . Interestingly, it has been reported that Smad6 represses BMP-induced Ids transcription through recruiting the transcriptional corepressor C-terminal binding protein [52] . This indicates that induction of Smad6 may promote TGF ␤ to induce EMT. 
Interrelationship between Growth Factors
The inverse effects of TGF ␤ /CTGF and BMP-7/HGF on the EMT process suggest that these growth factors are the main determinants that maintain the two cellular phenotypes, with CTGF acting as a brake to control the level of Smad7 [16] and allow the TGF ␤ signalling pathway. CTGF also rapidly activates all the intracellular signalling pathways known to cross-talk with the Smad signalling pathway via the activation of several receptor systems including TrkA/p75 NTR , integrins and LRP-2 [53] [54] [55] . Preliminary results indicate that CTGF also activates the TrkA receptor in tubular cells in vivo in a CTGFoverexpressing transgenic mouse [Wahab and Mason unpubl. results] . CTGF can also inhibit the BMPs-Smad signalling pathway by binding BMPs extracellularly [56] . Both TGF ␤ and BMP-7 counteract the activity of each other by cross-inducing their respective inhibitory Smads. Both growth factors may also induce the expression of other factors that can change the cellular environment and enhance their function. Figure 1 represents a model to illustrate this complex pattern of interaction.
Conclusion
In the adult kidney, the cellular phenotypes are maintained by a strict balance of growth factors. Chronic kidney diseases (regardless of the aetiology of the disease) are associated with increased TGF ␤ and CTGF expression levels which in turn have an inverse effect on the activity level of BMP-7 and HGF, leading to EMT of injured TECs and progression of chronic kidney diseases. Removal of injury, reduction in TGF ␤ /CTGF levels or increase in BMP7/HGF levels may lead to regression of these diseases. These growth factors already represent targets for therapeutic intervention in the treatment of renal diseases, but a more detailed understanding of the complex processes involved may lead to the further development of novel drugs.
